Abstract
With aging of the population, and a Western-type lifestyle, cancer has been the leading health problem in the developed world and a future threat for the society. The costs associated with cancer screening, prevention and particularly multidisciplinary treatment are being increased exponentially. Latest tumor-targeted therapies are very expensive and new drugs continuously are being developed and approved a further dramatic increase of insurance and governmental costs are expected. Hundreds of billions are funding the research for fighting cancer. But as latest cancer genome-based research reveals, the war against cancer is a hard task because of high complexity of the disease. Given this daunting challenge, can statins, which are the most commonly prescribed class of drugs worldwide, reduce mortality as a recently published study in the New England Journal of Medicine 1 , has suggested? Is such a simplified statistics from a database sufficient to save millions of lives instead of the effort to overcome myriad problems in understanding the dynamics of complex molecular mechanisms underlying cancer genome structure and function?

(Citation: Gastric & Breast Cancer 2012; 12(1): xx-xx)

Back

Full Text

PDF Version